Prediction of alpha-blocker response in men with benign prostatic hyperplasia by magnetic resonance imaging

Urology

Volumn 54, Issue 5, 1999, Pages 829-833

  Mimata, Hiromitsu ^a   Nomura, Yoshio ^a   Kasagi, Yasuhiro ^a   Satoh, Fuminori ^a   Emoto, Akio ^a   Li, Wenping ^a   Douno, Shintarou ^a   Mori, Hiromu ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; TAMSULOSIN;

ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; SCORING SYSTEM; TREATMENT OUTCOME; URINE FLOW RATE; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; PREDICTIVE VALUE OF TESTS; PROSTATIC HYPERPLASIA; SULFONAMIDES; URODYNAMICS;

EID: 0032745731     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(99)00258-7     Document Type: Article

References (17)

1. Caine M., Pfau A., Perlberg S. The use of alpha-adrenergic blockers in benign prostatic obstruction. Br J Urol. 48:1976;255-263.
2. Eri L.M., Tveter K.J. α-Blockade in the treatment of symptomatic benign prostatic hyperplasia. J Urol. 154:1995;923-934.
3. Shapiro E., Hartanto V., Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate. 21:1992;297-307.
4. Shiebler M.L., Tomaszewski J.E., Bezzi M., et al. Prostatic carcinoma and benign prostatic hyperplasia correlation of high-resolution MR and histopathologic findings . Radiology. 172:1989;131-137.
5. Ishida J., Sugimura K., Okizuka H., et al. Benign prostatic hyperplasia value of MR imaging for determining histologic type . Radiology. 190:1994;329-331.
6. Abrams P., Schulman C.C., Vaage S. Tamsulosin, a selective α1c-adrenoceptor antagonist a randomized, controlled trial in patients with benign prostatic 'obstruction' (symptomatic BPH) . Br J Urol. 76:1995;325-336.
7. Oesterling J.E. Benign prostatic hyperplasia medical and minimally invasive treatment options . N Engl J Med. 332:1995;99-109.
8. Lepor H. Medical therapy for benign prostatic hyperplasia. Urology. 42:1993;483-501.
9. Kawabe K., Ueno A., Takimoto Y., et al. Use of an α1-blocker, YM617, in the treatment of benign prostatic hyperplasia. J Urol. 144:1990;908-912.
10. Kawabe K. Efficacy and safety of tamsulosin in the treatment of benign prostatic hyperplasia. Br J Urol. 76:(suppl):1995;63-67.
11. Barry M.J., Cockett A.T.K., Holtgrewe H.L., et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol. 150:1993;351-358.
12. Roehrborn CG: The placebo effect in the treatment of benign prostatic hyperplasia, in Kirby R, McConnell J, Fitzpatrick J, et al (Eds): Textbook of Benign Prostatic Hyperplasia. Oxford, Isis Medical Media, 1996, pp 239-258.
13. Campo B. Benign prostatic hyperplasia should we always disobstruct or aim to cure the symptoms? Acta Urol Belg. 4:1995;125-126.
14. Hruban R.H., Zerhouni E.A., Dagher A.P., et al. Morphologic basis of MR imaging of benign prostatic hyperplasia. J Comput Assist Tomogr. 11:1987;1035-1041.
15. Ricci C., Cova M., Kang Y.S., et al. Normal age-related patterns of cellular and fatty bone marrow distribution in the axial skeleton MR imaging study . Radiology. 177:1990;83-88.
16. Hammerer P., Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol. 151:1994;99-102.
17. Shäfer W., Nopponey R., Rubben G., et al. The value of free flow rate and pressure-flow studies in the routine investigation of BPH patients. Neurourol Urodyn. 7:1988;219.